pexels-photo-5878503.jpeg
Photo by Artem Podrez on Pexels.com

News broke that UCT researchers are expected to start a clinical trial of hAd5 T-cell vaccine candidate

A new article explaining how UCT researchers are working on a clinical trial for a COVID-19 vaccine candidate, hAd5 T-cell. With the success of CAR-T therapy in recent years, this is an interesting development.

UCT researchers are expected to start a clinical trial of hAd5 T-cell vaccine candidate

UCT researchers are expected to start a clinical trial of hAd5 T-cell vaccine candidate, the first such trial in Africa. The trial will take place in Malawi and aims to evaluate how effectively this vaccine can prevent HIV infection.

What is the COVID-19 Vaccine?

The COVID-19 vaccine is a hAd5 T-cell vaccine trial that UCT researchers are expected to start. The vaccinated individuals will receive the new vaccine ten months after they’ve been given it. The efficacy of the trial will be evaluated over 18 months.

What are some Ad5 Vaccine Clinical Trials?

The UCT researchers are expected to start a clinical trial of hAd5 vaccine soon. This will be the first time that this vaccine will be tested on humans. The vaccine, which is already in use in animals, has been shown to slow the progression of HIV infection.

What are the benefits of this vaccine?

There are many benefits of this vaccine. The first is that it will reduce the risk of people getting leukemia. People who get this vaccine will also be immune to other cancers that are related to leukemia, such as lymphoma and myeloma. The final benefit of the vaccine is that it will delay or prevent people from developing autoimmune disorders by reactivating T-cells in the blood.

The different stages of trials

The different stages of trials include Phase 1, 2, 3, and 4. Each phase is designed to test the safety of the product without any risk to the patients. The first phase has no specific objectives but is to determine which dose should be used in future studies. Next are Phase 2/3 trials which are intended to determine the maximum tolerated dose. Finally, Phase 4 uses real-world people who have been vaccinated with hAd5 T-cell vaccine candidate to determine whether any side effects have occurred.

close
Business Edition Logo

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox

We don’t spam! Read our privacy policy for more info.